Robert C. Goldstein, MD, chief medical officer of Somnia Anesthesia, said in a blog post in response to the New York Times article that he supports the use of Propofol for colonoscopy. “Although using a general anesthetic administered by an anesthesiologist or nurse anesthetist may mean an added cost to the patient or insurance company for a colonoscopy, the health and financial benefits far outweigh the costs,” he said.
“In multiple studies conducted over the past few years, results have shown that use of a more potent drug, such as Propofol, for inducing anesthesia improves the polyp detection rates and cancer diagnosis rates, sometimes by as much as 43 percent. These early detections not only save lives, but often spare patients and insurance companies the long and costly process of cancer treatment,” said Dr. Goldstein.
More Articles on Somnia Anesthesia
Avoiding a Hurricane: How to Evaluate Your Anesthesia Provider and Ensure Your OR’s Success
Podcast Interview With Somnia Anesthesia’s Dr. Marc Koch: Evaluating Anesthesia Services
Evaluating Your Anesthesia Services — How to Assess Your Anesthesia Team
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
